Business Editors/Health & Medical Writers

BEDFORD, Mass. & SOLNA, Sweden--(BUSINESS WIRE)--July 22, 2002

Hologic, Inc. (NASDAQ: HOLX) and Siemens AG (NYSE:SI), today announced they have finalized the terms of the strategic alliance contemplated by their letter of intent entered into last November 2001.

Within the alliance, the companies have signed three separate agreements focused on the advancement of digital mammography technology:

- Siemens will source exclusively Hologic's DirectRay(TM) digital mammography flat detector technology for Siemens' Full Field Digital Mammography (FFDM) system.

- Hologic will license advanced image processing and display software developed by MeVis BreastCare GmbH&Co. KG, a Siemens affiliate.

- Siemens will be supported by Hologic to accelerate the time-to-market schedule for Siemens' FFDM product incorporating Hologic's DirectRay technology.

Under the DirectRay Supply Agreement, Hologic is adapting its patented DirectRay amorphous selenium direct-to-digital mammography technology to Siemens' FFDM system. During the term of this five-year agreement, Siemens has agreed to purchase its digital panel requirements for these systems exclusively from Hologic. Siemens will receive support from Hologic in its efforts to release the Siemens Digital Mammography system to the market, including the right to refer to Hologic's PMA applications.

In the other key part of the alliance, Hologic is cooperating with MeVis BreastCare GmbH&Co. KG, a Siemens affiliate, to source advanced image processing and display software aimed at providing an efficient, integrated approach to breast cancer detection. Such software is the core platform to construct a dedicated physician's workstation designed to improve workflow and patient throughput of FFDM systems.

"We believe that the combination of our synergistic technologies will represent a major step to define future standards in Digital Mammography," commented Holger Schmidt, President of Special Systems Division of Siemens Medical Solutions. "With the combination of Hologic's DirectRay(TM) flat panel and Siemens' workstation software, two Best-In-Class technologies are being merged. Siemens has selected Hologic's amorphous selenium flat panel, as this clearly defines second generation detector technology in mammography, which overcomes the shortfalls of other existing approaches. Hologic and Siemens will have the potential to define the new standards in Digital Mammography technology and our cooperation on time-to-market will significantly accelerate the timely release of Siemens' FFDM system. Offering second generation FFDM technology is another proof of our commitment to deliver a superior and comprehensive portfolio of Women's Health solutions."

"We are very excited about our growing relationship with Siemens, a global leader in medical imaging and mammography technology," said Hologic's President and CEO Jack Cumming. "We believe that Siemens commitment to our DirectRay amorphous selenium technology validates the superior quality of our product and strengthens our competitive position in the emerging digital mammography market going forward. In parallel, we have selected Siemens' advanced image processing and display software, as we see this far ahead of any other available products today. For Hologic and Siemens it will be an excellent base for offering advanced Soft-Copy Reading solutions, which are the key for our customers enhanced patient care, accelerated workflow and future cost savings. By combining forces, this alliance allows both companies to expand worldwide market penetration and brings Hologic and Siemens one step closer to the ultimate goal of bringing the first true, direct-to-digital mammography systems to market."

Siemens Medical Solutions of Siemens AG (NYSE: SI) with headquarters in Iselin, NJ and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is renowned for its innovative products, including imaging systems for diagnosis, therapy equipment for treatment, hearing instruments, and critical care and life support systems, as well as a wide array of information technology and data management solutions that optimize workflow and increase efficiency in hospitals, clinics and doctors' offices. The company is known as the premiere Application Service Provider processing more than 116 million transactions daily and managing more than 67 terabytes of data - twice the information volume of the Library of Congress.

Employing approximately 30,000 people worldwide, the company reported sales of 7.2 billion EUR, orders of 8.4 billion EUR and EBITA of 808 million EUR in fiscal 2001 (September 30). More information can be obtained by visiting us on the Web at www.siemensmedical.com.

Siemens AG, headquartered in Munich, is a leading global electronics and engineering company. It employs some 450,000 in 193 countries, and reported worldwide sales of more than $74 billion in fiscal 2001 (10/1/00 - 9/30/01). The United States is Siemens' largest market, with nearly 80,000 employees and sales of $18.9 billion for fiscal 2001. For more information about Siemens in the U.S., visit www.usa.siemens.com.

Hologic, Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to-digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information on Hologic, please visit the company's website at www.hologic.com.

This Press Release contains forward-looking information, including but not limited to statements involving Hologic's plans, expectations and intentions concerning its strategic alliance with Siemens, and the anticipated development and commercialization activities related to that alliance, including without limitation the performance of products developed through that alliance. Actual results may be materially different than those anticipated in these forward looking statements. Factors which could cause material differences to these forward looking statements include known and unknown risks, including without limitation, those set forth below. Strategic alliances involve numerous risks, including difficulties associated with cooperation and conflicts of interest among the parties. In addition, the technologies and planned business of the strategic alliance are subject to the significant risks and uncertainties generally applicable to high technology companies including: the uncertainty of new product development, including the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated, budget overruns, project delays, the early stage of development of the targeted markets, uncertainty of market growth, rapid technological change and intense competition, as well as other risks set forth in Hologic's filings with the Securities and Exchange Commission. Hologic cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.